$BSGM
BioSig Technologies, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224032374 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $13.00K $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.107M
YoY Change 111.69%
% of Gross Profit
Research & Development $156.0K $342.0K $1.700M
YoY Change -85.82% -79.88% 21.43%
% of Gross Profit
Depreciation & Amortization $26.59K $49.00K $92.00K
YoY Change -71.1% -46.74% 29.58%
% of Gross Profit
Operating Expenses $2.950M $5.305M $10.91M
YoY Change -27.2% -51.37% 90.57%
Operating Profit -$2.950M -$5.292M -$10.91M
YoY Change -27.18% -51.49% 90.83%
Interest Expense $3.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net $15.00K -$2.000K -$225.0K
YoY Change -99.11%
Pretax Income -$1.914M -$3.911M -$11.13M
YoY Change -52.74% -64.86% 94.72%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.914M -$3.915M -$11.09M
YoY Change -58.09% -64.71% 92.62%
Net Earnings / Revenue -30115.38%
Basic Earnings Per Share -$0.12 -$0.30 -$1.58
Diluted Earnings Per Share -$0.12 -$0.30 -$0.16
COMMON SHARES
Basic Shares Outstanding 16.28M shares 11.20M shares 70.49M shares
Diluted Shares Outstanding 16.20M shares 12.92M shares 7.028M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.354M
YoY Change -73.33%
Cash & Equivalents $615.0K $2.104M $1.300M
Short-Term Investments $102.0K
Other Short-Term Assets $423.0K
YoY Change -33.18%
Inventory $189.0K
Prepaid Expenses $113.0K $163.0K $418.0K
Receivables $81.00K $54.00K $21.00K
Other Receivables $5.000K
Total Short-Term Assets $848.0K $2.386M $1.987M
YoY Change -19.31% 20.08% -74.31%
LONG-TERM ASSETS
Property, Plant & Equipment $111.0K $137.0K $621.0K
YoY Change -81.28% -77.94% 4.19%
Goodwill
YoY Change
Intangibles $1.000K
YoY Change 0.0%
Long-Term Investments $69.00K
YoY Change
Other Assets $44.00K $514.0K
YoY Change -93.6% 1123.81%
Total Long-Term Assets $570.0K $721.0K $2.063M
YoY Change -72.9% -65.05% 11.27%
TOTAL ASSETS
Total Short-Term Assets $848.0K $2.386M $1.987M
Total Long-Term Assets $570.0K $721.0K $2.063M
Total Assets $1.418M $3.107M $4.050M
YoY Change -55.04% -23.28% -57.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $3.236M
YoY Change 80.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.701M $2.976M $3.332M
YoY Change -56.51% -10.68% 75.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $282.0K
YoY Change -53.69%
Total Long-Term Liabilities $15.00K $282.0K
YoY Change -94.68% -53.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.701M $2.976M $3.332M
Total Long-Term Liabilities $15.00K $282.0K
Total Liabilities $1.701M $2.991M $3.614M
YoY Change -58.55% -17.24% 44.1%
SHAREHOLDERS EQUITY
Retained Earnings -$254.2M -$252.3M -$234.4M
YoY Change 6.39% 7.65% 15.67%
Common Stock $17.00K $15.00K $73.00K
YoY Change -78.48% -79.45% 62.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$405.0K -$6.000K $242.0K
YoY Change
Total Liabilities & Shareholders Equity $1.418M $3.107M $4.050M
YoY Change -55.04% -23.28% -57.77%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.914M -$3.915M -$11.09M
YoY Change -58.09% -64.71% 92.62%
Depreciation, Depletion And Amortization $26.59K $49.00K $92.00K
YoY Change -71.1% -46.74% 29.58%
Cash From Operating Activities -$4.895M
YoY Change -26.97%
INVESTING ACTIVITIES
Capital Expenditures $77.00K
YoY Change -1640.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$77.00K
YoY Change 1440.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.812M
YoY Change 54.23%
NET CHANGE
Cash From Operating Activities -4.895M
Cash From Investing Activities -77.00K
Cash From Financing Activities 4.812M
Net Change In Cash -160.0K
YoY Change -95.54%
FREE CASH FLOW
Cash From Operating Activities -$4.895M
Capital Expenditures $77.00K
Free Cash Flow -$4.972M
YoY Change -25.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Revenues
Revenues
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q2 BSGM Stock Issued During Period Value Common Stock Issued For Exercise Of Warrants Cashlessly
StockIssuedDuringPeriodValueCommonStockIssuedForExerciseOfWarrantsCashlessly
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
us-gaap Gain Loss On Sale Of Accounts Receivable
GainLossOnSaleOfAccountsReceivable
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
us-gaap Stock Issued1
StockIssued1
usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
usd
CY2024Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
CY2024Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
usd
us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
usd
us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
usd
CY2024Q2 BSGM Accrued Reimbursements Current
AccruedReimbursementsCurrent
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsIntrinsicValue
usd
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
usd
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Expected To Vest Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestIntrinsicValue
usd
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
CY2024Q2 us-gaap Other Assets
OtherAssets
44000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
44000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
15000 usd
CY2024Q2 us-gaap Revenues
Revenues
13000 usd
us-gaap Revenues
Revenues
27000 usd
us-gaap Revenues
Revenues
5000 usd
CY2024Q2 us-gaap Revenues
Revenues
13000 usd
us-gaap Revenues
Revenues
27000 usd
us-gaap Revenues
Revenues
5000 usd
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
127000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000 usd
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-225000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1097000 usd
CY2023Q1 BSGM Stock Issued During Period Value Issued In Settlement Of Debt
StockIssuedDuringPeriodValueIssuedInSettlementOfDebt
105000 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
482000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6748000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1052000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7382000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1910000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1910000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4811000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
201000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3245000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3245000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1567000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-69000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
3000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11130000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
331000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
331000 usd
us-gaap Profit Loss
ProfitLoss
-7326000 usd
us-gaap Profit Loss
ProfitLoss
-18512000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
127000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
155000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
144000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1307000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
253000 usd
us-gaap Gain Loss On Sale Of Accounts Receivable
GainLossOnSaleOfAccountsReceivable
-1388000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5493000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6891000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
30000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12000 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-51000 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-50000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-5000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-42000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
564000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2776000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
159000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-170000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-153000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2795000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10543000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4209000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9993000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
1567000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4709000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11560000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1914000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
895000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2104000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1252000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
122000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
105000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
5000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
5000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
133000 usd
us-gaap Stock Issued1
StockIssued1
509000 usd
CY2024Q1 us-gaap Auction Market Preferred Securities Stock Series Liquidation Value
AuctionMarketPreferredSecuritiesStockSeriesLiquidationValue
35000000 usd
CY2024Q2 us-gaap Cash
Cash
2100000 usd
CY2024Q2 BSGM Working Capital Deficit
WorkingCapitalDeficit
600000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2800000 usd
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse stock split
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zEXCsKVviF4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zbtX4cl5VlJg">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Payments For Rent
PaymentsForRent
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
BSGM Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zpzQ2ADRJOF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_z9va3KhyPI9k">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At June 30, 2024 and December 31, 2023, deposits in excess of FDIC limits were $<span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_pn4n6_c20240630_zJ0xf2bi1UR9" title="Cash, uninsured amount">1.85</span> million and <span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_dxL_c20231231_zigdYVOSyaA6" title="Cash, uninsured amount::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0887">nil</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1850000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
253000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7143443 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1657170 shares
CY2024Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4752 usd
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4752 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
9504 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
9603 usd
CY2024Q2 us-gaap Product Warranty Obligation Term
ProductWarrantyObligationTerm
P2Y
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1036000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1452000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
899000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
943000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
509000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
253411 usd
CY2024Q2 us-gaap Depreciation
Depreciation
43837 usd
CY2023Q2 us-gaap Depreciation
Depreciation
86680 usd
us-gaap Depreciation
Depreciation
117213 usd
us-gaap Depreciation
Depreciation
166148 usd
BSGM Number Of Leases
NumberOfLeases
2 integer
CY2023 BSGM Number Of Leases
NumberOfLeases
2 integer
us-gaap Operating Lease Payments
OperatingLeasePayments
30544 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
29995 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
expiring through July 31, 2025
CY2023 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
expiring through July 31, 2025
CY2024Q2 BSGM Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2023Q4 BSGM Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2024Q2 BSGM Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
738000 usd
CY2023Q4 BSGM Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
583000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
257000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
412000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
71928 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
93057 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
162715 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
184577 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
282000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
452000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
267000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
349000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
103000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
186000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
106000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
292000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
282000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
68000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
84000 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
2000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
72000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
93000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
143000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
168000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
8000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
3000 usd
us-gaap Lease Cost
LeaseCost
163000 usd
us-gaap Lease Cost
LeaseCost
185000 usd
CY2022 us-gaap Payments For Rent
PaymentsForRent
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
BSGM Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2024Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2023Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
120000 usd
BSGM Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-55000 usd
CY2024Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2024Q2 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
69000 usd
CY2022Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
221000 usd
BSGM Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-53000 usd
CY2023Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
3000 usd
CY2023Q2 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
171000 usd
CY2024Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear
53000 usd
CY2024Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
13000 usd
CY2024Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2024Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
70000 usd
CY2024Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount
SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
1000 usd
CY2024Q2 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
69000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1259000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1277000 usd
CY2023Q4 BSGM Accrued Reimbursements Current
AccruedReimbursementsCurrent
9000 usd
CY2024Q2 BSGM Accrued Consulting Current
AccruedConsultingCurrent
152000 usd
CY2023Q4 BSGM Accrued Consulting Current
AccruedConsultingCurrent
804000 usd
CY2024Q2 BSGM Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
467000 usd
CY2023Q4 BSGM Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
802000 usd
CY2024Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
62000 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
333000 usd
CY2024Q2 BSGM Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
414000 usd
CY2023Q4 BSGM Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
290000 usd
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
250000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
601000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2604000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4116000 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse stock split
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15110846 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15110846 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9040043 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9040043 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
109948 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P10Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
118700 shares
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
115481 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
603229 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.67
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
484529 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.86
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
118700 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M4D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
115481 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
0.350
CY2024Q2 BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Values
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValues
157417 usd
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Values
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValues
154735 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
386336 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
639523 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
21550 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y6M
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4951068 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
2748371 shares
CY2023Q4 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
7.40
CY2023 BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2023Q4 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
1717104000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
2202697 shares
BSGM Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
2.28
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Grants Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm2
P5Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
4951068 shares
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
4.92
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
P4Y
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVest
4429002 shares
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestWeightedAverageExercisePrice
7.21
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Vested And Expected To Vest Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm2
P3Y7M6D
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
4429002 shares
CY2024Q2 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
5.28
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm2
P3Y10M24D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder.
CY2024Q2 BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
27000 usd
CY2024Q2 BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.15 pure
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000 usd
CY2023Q2 BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
-137000 usd
CY2023Q2 BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.27 pure
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-37000 usd
BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
-17000 usd
BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.52 pure
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
-299000 usd
BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.29 pure
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-87000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
26000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
17000 usd
CY2024Q2 BSGM Defined Contribution Plan Cost Recognizeds
DefinedContributionPlanCostRecognizeds
47599 usd
BSGM Defined Contribution Plan Cost Recognizeds
DefinedContributionPlanCostRecognizeds
25904 usd
CY2023Q2 BSGM Defined Contribution Plan Cost Recognizeds
DefinedContributionPlanCostRecognizeds
63818 usd
BSGM Defined Contribution Plan Cost Recognizeds
DefinedContributionPlanCostRecognizeds
129737 usd
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1876053 usd
CY2023Q4 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
775782 usd
CY2024Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1440000 usd
CY2024Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
288000 usd
CY2024Q2 us-gaap Revenues
Revenues
13000 usd
us-gaap Revenues
Revenues
27000 usd
us-gaap Revenues
Revenues
5000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
5305000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10908000 usd
us-gaap Operating Expenses
OperatingExpenses
8756000 usd
us-gaap Operating Expenses
OperatingExpenses
18299000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5292000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10908000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8729000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18294000 usd
CY2024Q2 us-gaap Assets
Assets
3107000 usd
CY2023Q4 us-gaap Assets
Assets
1798000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
15000 usd

Files In Submission

Name View Source Status
bsgm-20240630_cal.xml Edgar Link unprocessable
0001493152-24-032374-index-headers.html Edgar Link pending
0001493152-24-032374-index.html Edgar Link pending
0001493152-24-032374.txt Edgar Link pending
0001493152-24-032374-xbrl.zip Edgar Link pending
bsgm-20240630.xsd Edgar Link pending
ex31-01.htm Edgar Link pending
ex31-02.htm Edgar Link pending
ex32-01.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
bsgm-20240630_def.xml Edgar Link unprocessable
bsgm-20240630_lab.xml Edgar Link unprocessable
bsgm-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending